Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
The CDC defines severe obesity, or class III obesity, as any patient with a BMI of 40 or higher. TAVR among these patients is not associated with a lower survival rate, but it does lead to many more risks.
Heart teams can limit the risk of conduction disturbances that lead to permanent pacemaker implantation by utilizing both the cusp-overlap method and intracardiac echocardiography.
When patients with pacemakers die, what happens to the device? Typically, it ends up being discarded and forgotten—they were designed to be single-use devices, after all—but that does not have to be the case.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
